| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Stryker Corporation$306.95
-3.65 (-1.18%)
D 37Pipeline Score MedTech · Commercial
Market Cap
121.33 B
EPS
8.72
P/E Ratio
36.66 $
Value Trade
644.62 M
SEC Financials
Q1 2026Dilution Risk
Revenue
6.02 B
R&D Expenses
413.00 M
Operating CF
581.00 M
Total Assets
46.29 B
Total Liabilities
23.31 B
Equity
22.98 B
D/E Ratio
12,345
2.13 %
Week
-3.44 %
1 Month
-15.49 %
3 Month
-12.83 %
6 Month
23.84 %
5 Year
379,668.4 %
All Time
Cash Data
Cash Position
2.96 B
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
May 11, 2026
Overview
Volume
212.17 K
52 Week Range
281 - 404.87
% held by Insiders
5.98 %
% held by Institutions
79.97 %
Enterprise Value
133.60 B
Total Shares
382.56 M
Short %
1.81 %
Float Shares
345.45 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
D37
Pipeline Score $452M
Pipeline ValueValuation Signal
3
Drugs Scored0.0x
rNPV / MCap Top 50%
Large Pharma (rank 453 of 905)
Percentile RankStryker Corporation faces pipeline headwinds (37/100), with $452M risk-adjusted pipeline value, led by Bone morphogenetic protein 7 in Osteoarthritis of the Knee (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bone morphogenetic protein 7 Small molecule | Osteoarthritis of the Knee | Phase 2 | NCT01133613 | 17% | $306M | COMPLETED | 406 | - | - | Oct 1, 2011 | - | Feb 1, 2012 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in SYK
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
SYK
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
SYK
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
SYK
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
SYK Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
SYK Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2028-01-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2028-01-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2028-01-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
SYKStryker launches TPX HD® power tool, supporting demanding orthopaedic procedures
Stryker has launched the TPX HD power tool, aimed at enhancing performance in challenging orthopedic procedures. The tool is designed for total joint revisions and minimally invasive surgeries, featuring improved ergonomics and customizable control. Key attributes include increased torque and speed, making it a reliable choice for surgeons during demanding cases.
Read more →SYKStryker lanceert Pangea Plating System en voltooit de eerste case in Europa
Stryker has launched the Pangea Plating System and completed its first case in Europe. This new system aims to enhance surgical procedures, although specific details about its features and benefits were not disclosed in the article. The launch marks a significant step for Stryker in expanding its offerings in the European market.
Read more →SYKStryker bringt das Pangea-Plattensystem auf den Markt und schließt den ersten Eingriff in Europa ab
Stryker has introduced its Pangea plate system, marking a significant advancement in surgical technology. The company has successfully completed the first procedure using this system in Europe. This launch is expected to improve surgical outcomes and patient care in the region.
Read more →SYKBioStar Capital-Backed Amplitude Vascular Systems’ $835M Acquisition by Stryker Reflects Strength of Michigan’s Medtech Ecosystem
Stryker's acquisition of Amplitude Vascular Systems for $835 million underscores the robustness of Michigan's medtech industry. This strategic move reflects a growing confidence among investors and stakeholders in the sector's future. The partnership is expected to enhance Stryker's portfolio and drive innovation in vascular solutions.
Read more →SYKStryker completes acquisition of Amplitude Vascular Systems to add next-generation IVL technology to peripheral vascular portfolio
Stryker has completed the acquisition of Amplitude Vascular Systems, enhancing its peripheral vascular portfolio with next-generation intravascular lithotripsy technology. This acquisition is expected to improve treatment for complex peripheral arterial disease. Stryker aims to leverage AVS's innovative technology to better support physicians and patient outcomes.
Read more →SYKStryker to participate in the Bank of America Securities 2026 Global Healthcare Conference
Stryker (NYSE:SYK) will participate in the Bank of America Securities 2026 Global Healthcare Conference on May 13, 2026. Key executives, including President Spencer Stiles, will present at the event. A live webcast of the presentation will be available on Stryker's website, ensuring investor access.
Read more →SYKStryker reports first quarter 2026 operating results
Stryker reported a 2.6% increase in net sales for Q1 2026, totaling $6.0 billion. The company experienced a 14.2% rise in reported EPS, although adjusted EPS fell by 8.5%. CEO Kevin A. Lobo expressed confidence in meeting full-year guidance for organic sales growth, despite a contraction in adjusted operating income margin.
Read more →SYKStryker signs definitive agreement to acquire Amplitude Vascular Systems to add next-generation IVL technology to peripheral vascular portfolio
Stryker has signed a definitive agreement to acquire Amplitude Vascular Systems, enhancing its Peripheral Vascular portfolio with advanced intravascular lithotripsy technology. This acquisition aims to address significant clinical needs in treating calcified peripheral arterial disease. The technology promises improved treatment efficiency and is expected to grow in adoption among physicians.
Read more →SYKStryker to announce financial results for its first quarter of fiscal year 2026
Stryker Corporation will announce its financial results for the first quarter of fiscal year 2026 on April 30, 2026. A press release will be available at 4:05 p.m. ET, followed by a webcast at 4:30 p.m. ET to discuss the results. The company is known for its innovative medical technologies.
Read more →SYKStryker names Nick Mead Vice President, Investor Relations
Stryker has appointed Nick Mead as Vice President of Investor Relations, effective May 1, 2026. Mead, who has nearly 20 years of experience within the company, previously served as Vice President of Finance for the Medical division. His appointment is expected to strengthen Stryker's investor relations and support its strategic goals.
Read more →SYKStryker announces Annual Meeting of Shareholders
Stryker Corporation has announced its 2026 Annual Meeting of Shareholders, scheduled for May 6, 2026, at 12:00 p.m. Eastern Time. The meeting will be held virtually, with a webcast available for attendees. A recording will be accessible the following day, ensuring shareholders can review the meeting details.
Read more →SYKStryker launches Synchfix™ EVT, expanding options for flexible syndesmotic fixation
Stryker has launched Synchfix EVT, a next-generation flexible syndesmotic fixation device aimed at improving surgical efficiency and patient care. The device, which will be featured at the 2026 ACFAS Annual Meeting, simplifies deployment and is the first of its kind indicated for adolescent patients. Its innovative design has received the Red Dot Design Award, highlighting its advancements over previous models.
Read more →SYKStryker introduces Mako Handheld Robotics with the limited market release of Mako RPS
Stryker has announced the limited market release of its Mako RPS, a handheld robotic system designed for Total Knee procedures. This new platform integrates Stryker's robotics and power tool technologies, providing surgeons with a familiar experience while enhancing surgical precision. Mako RPS is compatible with Stryker's Triathlon Total Knee System and aims to improve patient outcomes in orthopaedic surgeries.
Read more →SYKStryker declares an $0.88 per share quarterly dividend
Stryker Corporation has declared a quarterly dividend of $0.88 per share, payable on April 30, 2026. This represents a 4.8% increase from the previous year, maintaining the same rate as the last quarter. The announcement reflects Stryker's commitment to returning value to shareholders while continuing to impact healthcare positively.
Read more →SYKStryker to announce financial results for its fourth quarter and full year 2025
Stryker Corporation announced it will release its financial results for the fourth quarter and full year 2025 on January 29, 2026. A press release will be issued at 4:05 p.m. ET, followed by a webcast at 4:30 p.m. ET to discuss the results. The company emphasizes its commitment to improving healthcare outcomes.
Read more →SYKStryker names Spencer Stiles President and Chief Operating Officer
Stryker has appointed Spencer Stiles as President and Chief Operating Officer, effective January 1, 2026. Stiles, a veteran with 27 years at Stryker, will oversee global businesses and strategy. His leadership is expected to drive growth and innovation. Dylan Crotty will succeed him as Group President of Orthopaedics.
Read more →SYKStryker reports third quarter 2025 operating results
Stryker reported robust third quarter results for 2025, with net sales reaching $6.1 billion, a 10.3% increase. The company achieved double-digit growth in adjusted earnings per share and raised its full-year guidance. The performance was driven by strong demand across its MedSurg and Neurotechnology segments, contributing significantly to overall sales growth.
Read more →SYKStryker to announce financial results for its third quarter of fiscal year 2025
Stryker (NYSE:SYK) will announce its financial results for the third quarter of fiscal year 2025 on October 30, 2025. A press release will be issued at 4:05 p.m. ET, followed by a webcast at 4:30 p.m. ET to discuss the results. The company aims to provide insights into its performance for the quarter ending September 30, 2025.
Read more →SYKStryker to host investor day
Stryker will hold an Investor Day on November 13, 2025, at 2:30 p.m. ET in Mahwah, New Jersey. The event will feature a live audio webcast, which will also be available for replay on their official website. This initiative reflects Stryker's commitment to transparency and investor engagement.
Read more →SYKStryker to participate in the 2025 Wells Fargo Securities Healthcare Conference
Stryker will participate in the 2025 Wells Fargo Securities Healthcare Conference on September 4. Key executives, including Andy Pierce and Jason Beach, will engage in a Fireside Chat. A live audio webcast of the session will be available on Stryker's website, ensuring accessibility for stakeholders.
Read more →SYKStryker declares an $0.84 per share quarterly dividend
Stryker Corporation has announced a quarterly dividend of $0.84 per share, payable on October 31, 2025, to shareholders on record as of September 30, 2025. This marks a 5.0% increase from the previous year, while remaining unchanged from the last quarter. The announcement reflects Stryker's ongoing commitment to returning value to its shareholders.
Read more →SYKStryker reports second quarter 2025 operating results
Stryker reported strong operating results for Q2 2025, with net sales reaching $6.0 billion, reflecting an 11.1% increase. The company experienced significant growth in its MedSurg and Neurotechnology segments, while also raising its full-year guidance for organic net sales growth. Adjusted net earnings per diluted share rose to $3.13, marking an 11.4% increase compared to the previous year.
Read more →SYKStryker to participate in the Bank of America Securities 2025 Global Healthcare Conference
Stryker will participate in the Bank of America Securities 2025 Global Healthcare Conference on May 13, 2025. The presentation will be led by CFO Preston Wells and VP Jason Beach at 1:40 p.m. PT. A live webcast will be available on Stryker's website, ensuring accessibility for investors and stakeholders.
Read more →Competitive Position
How SYK ranks across every disease it competes inCompetitive Position is a premium feature
See how SYK ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial